New cases of δ‐aminolevulinic acid dehydratase deficiency: Functional insights into gene variants using an innovative mouse liver model
Year: 2025
Type: article
Abstract: BACKGROUND: Dysfunction of δ-aminolevulinic acid dehydratase (ALAD), the second enzyme involved in heme biosynthesis, leads to two pathologies: genetic and acquired. The genetic form is an ultrarare, severe childhood-onset disease inherited in an autosomal recessive manner, whereas the acquired form usually affects adults due to enzyme inhibition by specific chemicals. AIMS AND PATIENT COHORT: This study reports the molecular characterization of three pediatric patients with genetic ALAD deficiency porphyria (ADP), including two siblings, and five adults who exhibited features suggestive of heavy metal poisoning. Furthermore, using an innovative mouse liver model, we performed in vivo functional analysis of the pathogenic variants and lead susceptibility alleles identified in the ALAD gene. RESULTS: Siblings (one female) were found to carry the c440_441delinsTT (p.Arg147Leu) variant in homozygosis. However, the vector expression system confirmed a pathogenic role only for the c.440C > T substitution. The third patient exhibited compound heterozygosity, with a c.839G > A (p.Gly280Glu) dominant variant and a hypomorphic c.724G > A (p.Val242Ile) allele. The rs1805313 and rs8177800 common intron variants were most prevalent in patients with acquired ADP. However, increased ALAD activity for the rs1139488 synonymous variant and a hexameric ALAD conformation for the rs1800435 missense variant have been established. CONCLUSION: These findings underscore the molecular heterogeneity of the ALAD gene and present the first reported case of ADP in a female patient.
Source: Journal of Internal Medicine
DOI: 10.1111/joim.70044
Authors: Elena Di Pierro, Isabel Solares, Daniel Jericó, Francisco J. Castelbón, Javier Tomás Solera, Antoni Riera‐Mestre, María Barreda‐Sánchez, Carlo Poci, Annamaria Nicolli, Francesco Urigo, Ana Sampedro, Rafael Enríquez de Salamanca, Matteo Marcacci, Matías A. Ávila, Pauline Harper, Marta G. Fanlo‐Maresma, Encarna Guillén‐Navarro, Giovanna Graziadei, Andrea Wenzel, Bodo B. Beck, Paolo Ventura, Montserrat Morales‐Conejo, Antonio Fontanellas
Institutions: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre, Hospital Universitario 12 De Octubre, Clinica Universidad de Navarra, Universidad de Navarra, Navarre Institute of Health Research, Centro de Investigación Médica Aplicada, Instituto de Salud Carlos III, Centre for Biomedical Network Research on Rare Diseases, Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition, Bellvitge University Hospital, Institut d'Investigació Biomédica de Bellvitge, Universitat de Barcelona, Universidad Católica de Murcia, University of Padua, Azienda Ospedale - Università Padova, University of Modena and Reggio Emilia, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Karolinska University Hospital, Karolinska Institutet, Instituto Murciano de Investigación Biosanitaria, Hospital Universitario Virgen de la Arrixaca, Universidad de Murcia, University of Cologne
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,780
Awards: Evaluación de medicamentos innovadores basados en ARN en la corrección de las vías metabólicas de hemo, glicolípidos y homocisteína en pacientes con porfiria aguda intermitente y modelos experimentales de ratón y primates-no-humanos., Medicina de precisión en porfirias: desarrollo de terapias de ARNm, mecanismos subyacentes al mayor riesgo de carcinogénesis hepática e intervenciones basadas en microbiomas para modular la resistencia a la insulina.
OpenAlex ID: W4416459084
